2024-10-18 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
IRWD
Ironwood Pharmaceuticals, Inc.
|
Buy |
10.2% |
4.23% |
2024-10-03 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.76% |
-0.32% |
2024-10-07 |
ARDX
Ardelyx, Inc.
|
Buy |
9.38% |
-3.48% |
2024-10-14 |
BKD
Brookdale Senior Living Inc.
|
Buy |
10.62% |
9.26% |
2024-10-15 |
ARWR
Arrowhead Pharmaceuticals, Inc.
|
Buy |
10.46% |
7.64% |
2024-10-15 |
VCEL
Vericel Corporation
|
Buy |
9.39% |
-3.37% |
2024-10-15 |
CDXS
Codexis, Inc.
|
Buy |
9.65% |
-0.59% |
2024-10-16 |
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
9.41% |
-3.09% |
2024-10-16 |
VREX
Varex Imaging Corporation
|
Buy |
9.56% |
0% |
2024-10-18 |
NKTR
Nektar Therapeutics
|
Buy |
9.56% |
0% |
2024-10-18 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
RDNT |
Sell
All
|
-3.2% |
Assets Rebalanced
None
2024-10-16 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
IRWD
Ironwood Pharmaceuticals, Inc.
|
Buy |
10.07% |
3.05% |
2024-10-03 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
10.16% |
3.9% |
2024-10-07 |
ARDX
Ardelyx, Inc.
|
Buy |
9.59% |
-1.16% |
2024-10-14 |
BKD
Brookdale Senior Living Inc.
|
Buy |
9.73% |
0.33% |
2024-10-15 |
ARWR
Arrowhead Pharmaceuticals, Inc.
|
Buy |
9.96% |
2.69% |
2024-10-15 |
VCEL
Vericel Corporation
|
Buy |
9.67% |
-0.33% |
2024-10-15 |
RDNT
RadNet, Inc.
|
Buy |
9.72% |
0.2% |
2024-10-15 |
CDXS
Codexis, Inc.
|
Buy |
9.7% |
0% |
2024-10-16 |
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
9.7% |
0% |
2024-10-16 |
The percentage of cash held in the portfolio is:
11.7%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-10-15 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
IRWD
Ironwood Pharmaceuticals, Inc.
|
Buy |
9.93% |
0.7% |
2024-10-03 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.89% |
0.32% |
2024-10-07 |
ARDX
Ardelyx, Inc.
|
Buy |
9.7% |
-0.83% |
2024-10-14 |
BKD
Brookdale Senior Living Inc.
|
Buy |
9.78% |
0% |
2024-10-15 |
ARWR
Arrowhead Pharmaceuticals, Inc.
|
Buy |
9.78% |
0% |
2024-10-15 |
VCEL
Vericel Corporation
|
Buy |
9.78% |
0% |
2024-10-15 |
RDNT
RadNet, Inc.
|
Buy |
9.78% |
0% |
2024-10-15 |
The percentage of cash held in the portfolio is:
31.35%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-10-14 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
IRWD
Ironwood Pharmaceuticals, Inc.
|
Buy |
9.86% |
0% |
2024-10-03 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.83% |
-0.32% |
2024-10-07 |
ARDX
Ardelyx, Inc.
|
Buy |
9.79% |
0% |
2024-10-14 |
The percentage of cash held in the portfolio is:
70.52%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-10-11 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
IRWD
Ironwood Pharmaceuticals, Inc.
|
Buy |
9.77% |
-1.17% |
2024-10-03 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.7% |
-1.95% |
2024-10-07 |
The percentage of cash held in the portfolio is:
80.53%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
BCRX |
Sell
All
|
-6.07% |
Assets Rebalanced
None
2024-10-07 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
IRWD
Ironwood Pharmaceuticals, Inc.
|
Buy |
9.88% |
0.94% |
2024-10-03 |
BCRX
BioCryst Pharmaceuticals, Inc.
|
Buy |
9.79% |
0% |
2024-10-07 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.79% |
0% |
2024-10-07 |
The percentage of cash held in the portfolio is:
70.54%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-10-03 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
IRWD
Ironwood Pharmaceuticals, Inc.
|
Buy |
9.8% |
0% |
2024-10-03 |
The percentage of cash held in the portfolio is:
90.2%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-09-26 00:00:00
: Portfolio change date
No Asset in the portfolio
The percentage of cash held in the portfolio is:
100%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
NVCR |
Sell
All
|
-11.63% |
Assets Rebalanced
None
2024-09-25 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
NVCR
NovoCure Limited
|
Buy |
8.11% |
-8.98% |
2024-09-06 |
The percentage of cash held in the portfolio is:
91.89%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
MYGN |
Sell
All
|
-1.56% |
Assets Rebalanced
None
2024-09-24 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
NVCR
NovoCure Limited
|
Buy |
8.15% |
-8.42% |
2024-09-06 |
MYGN
Myriad Genetics, Inc.
|
Buy |
8.74% |
-0.15% |
2024-09-09 |
The percentage of cash held in the portfolio is:
83.11%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
ESPR |
Sell
All
|
-10.93% |
Assets Rebalanced
None
2024-09-19 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
8.57% |
-4.92% |
2024-09-04 |
NVCR
NovoCure Limited
|
Buy |
8.54% |
-2.44% |
2024-09-06 |
MYGN
Myriad Genetics, Inc.
|
Buy |
9.1% |
5.56% |
2024-09-09 |
The percentage of cash held in the portfolio is:
73.78%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
PODD |
Sell
All
|
15.5% |
Assets Rebalanced
None
2024-09-17 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
PODD
Insulet Corporation
|
Buy |
11.32% |
14.42% |
2024-08-29 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
8.68% |
-3.83% |
2024-09-04 |
NVCR
NovoCure Limited
|
Buy |
8.72% |
-0.5% |
2024-09-06 |
MYGN
Myriad Genetics, Inc.
|
Buy |
8.92% |
3.45% |
2024-09-09 |
The percentage of cash held in the portfolio is:
62.37%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
AADI |
Sell
All
|
7.43% |
TVTX |
Sell
All
|
48.65% |
Assets Rebalanced
None
2024-09-13 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
AADI
Aadi Bioscience, Inc.
|
Buy |
10.3% |
1.14% |
2024-08-27 |
PODD
Insulet Corporation
|
Buy |
11.52% |
12.73% |
2024-08-29 |
TVTX
Travere Therapeutics, Inc.
|
Buy |
12.23% |
31.25% |
2024-09-04 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
8.91% |
-4.37% |
2024-09-04 |
NVCR
NovoCure Limited
|
Buy |
8.69% |
-3.99% |
2024-09-06 |
MYGN
Myriad Genetics, Inc.
|
Buy |
8.71% |
-2.15% |
2024-09-09 |
The percentage of cash held in the portfolio is:
39.64%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
AGEN |
Sell
All
|
8.41% |
Assets Rebalanced
None
2024-09-12 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
AGEN
Agenus Inc.
|
Buy |
10.59% |
3.11% |
2024-08-23 |
AADI
Aadi Bioscience, Inc.
|
Buy |
10.79% |
5.14% |
2024-08-27 |
PODD
Insulet Corporation
|
Buy |
11.47% |
11.4% |
2024-08-29 |
TVTX
Travere Therapeutics, Inc.
|
Buy |
11.97% |
27.5% |
2024-09-04 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
8.93% |
-4.92% |
2024-09-04 |
NVCR
NovoCure Limited
|
Buy |
8.7% |
-4.54% |
2024-09-06 |
MYGN
Myriad Genetics, Inc.
|
Buy |
8.74% |
-2.56% |
2024-09-09 |
The percentage of cash held in the portfolio is:
28.8%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
APLS |
Sell
All
|
-3.75% |
Assets Rebalanced
None
2024-09-11 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
10.09% |
-1.69% |
2024-08-22 |
AGEN
Agenus Inc.
|
Buy |
10.25% |
-0.18% |
2024-08-23 |
AADI
Aadi Bioscience, Inc.
|
Buy |
10.43% |
1.71% |
2024-08-27 |
PODD
Insulet Corporation
|
Buy |
11.4% |
10.8% |
2024-08-29 |
TVTX
Travere Therapeutics, Inc.
|
Buy |
12.55% |
33.75% |
2024-09-04 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
8.87% |
-5.46% |
2024-09-04 |
NVCR
NovoCure Limited
|
Buy |
8.53% |
-6.37% |
2024-09-06 |
MYGN
Myriad Genetics, Inc.
|
Buy |
8.99% |
0.26% |
2024-09-09 |
The percentage of cash held in the portfolio is:
18.9%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
CARA |
Sell
All
|
-18.08% |
Assets Rebalanced
None
2024-09-10 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
10.29% |
0.21% |
2024-08-22 |
CARA
Cara Therapeutics, Inc.
|
Buy |
9.28% |
-9.62% |
2024-08-23 |
AGEN
Agenus Inc.
|
Buy |
9.63% |
-6.22% |
2024-08-23 |
AADI
Aadi Bioscience, Inc.
|
Buy |
10.61% |
3.43% |
2024-08-27 |
PODD
Insulet Corporation
|
Buy |
11.03% |
7.2% |
2024-08-29 |
TVTX
Travere Therapeutics, Inc.
|
Buy |
12.57% |
33.96% |
2024-09-04 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
8.71% |
-7.1% |
2024-09-04 |
NVCR
NovoCure Limited
|
Buy |
8.38% |
-7.98% |
2024-09-06 |
MYGN
Myriad Genetics, Inc.
|
Buy |
9.02% |
0.63% |
2024-09-09 |
The percentage of cash held in the portfolio is:
10.49%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
ALDX |
Sell
All
|
-6.49% |
Assets Rebalanced
None
2024-09-09 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
10.73% |
3% |
2024-08-22 |
CARA
Cara Therapeutics, Inc.
|
Buy |
9.78% |
-6.12% |
2024-08-23 |
AGEN
Agenus Inc.
|
Buy |
9.43% |
-9.51% |
2024-08-23 |
AADI
Aadi Bioscience, Inc.
|
Buy |
10.89% |
4.57% |
2024-08-27 |
PODD
Insulet Corporation
|
Buy |
10.97% |
5.05% |
2024-08-29 |
TVTX
Travere Therapeutics, Inc.
|
Buy |
10.89% |
14.37% |
2024-09-04 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
8.59% |
-9.84% |
2024-09-04 |
ALDX
Aldeyra Therapeutics, Inc.
|
Buy |
8.97% |
-3.01% |
2024-09-05 |
NVCR
NovoCure Limited
|
Buy |
8.65% |
-6.48% |
2024-09-06 |
MYGN
Myriad Genetics, Inc.
|
Buy |
9.1% |
0% |
2024-09-09 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
ORGO |
Sell
All
|
-12.72% |
Assets Rebalanced
None
2024-09-06 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
10.24% |
-1.42% |
2024-08-22 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.69% |
-6.71% |
2024-08-22 |
CARA
Cara Therapeutics, Inc.
|
Buy |
9.72% |
-6.41% |
2024-08-23 |
AGEN
Agenus Inc.
|
Buy |
9.5% |
-8.59% |
2024-08-23 |
AADI
Aadi Bioscience, Inc.
|
Buy |
10.67% |
2.86% |
2024-08-27 |
PODD
Insulet Corporation
|
Buy |
11.01% |
5.72% |
2024-08-29 |
TVTX
Travere Therapeutics, Inc.
|
Buy |
9.82% |
3.44% |
2024-09-04 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
8.92% |
-6.01% |
2024-09-04 |
ALDX
Aldeyra Therapeutics, Inc.
|
Buy |
9.22% |
0% |
2024-09-05 |
NVCR
NovoCure Limited
|
Buy |
9.22% |
0% |
2024-09-06 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-09-05 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
9.84% |
-5.21% |
2024-08-22 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.91% |
-4.59% |
2024-08-22 |
CARA
Cara Therapeutics, Inc.
|
Buy |
9.75% |
-6.12% |
2024-08-23 |
AGEN
Agenus Inc.
|
Buy |
9.21% |
-11.33% |
2024-08-23 |
AADI
Aadi Bioscience, Inc.
|
Buy |
10.67% |
2.86% |
2024-08-27 |
PODD
Insulet Corporation
|
Buy |
10.82% |
3.96% |
2024-08-29 |
TVTX
Travere Therapeutics, Inc.
|
Buy |
9.93% |
4.69% |
2024-09-04 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
9.44% |
-0.55% |
2024-09-04 |
ALDX
Aldeyra Therapeutics, Inc.
|
Buy |
9.21% |
0% |
2024-09-05 |
The percentage of cash held in the portfolio is:
11.21%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
CERS |
Sell
All
|
-11.34% |
EGRX |
Sell
All
|
-11.35% |
Assets Rebalanced
None
2024-09-04 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
10.08% |
-2.65% |
2024-08-22 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.99% |
-3.53% |
2024-08-22 |
CARA
Cara Therapeutics, Inc.
|
Buy |
10% |
-3.5% |
2024-08-23 |
AGEN
Agenus Inc.
|
Buy |
9.38% |
-9.51% |
2024-08-23 |
CERS
Cerus Corporation
|
Buy |
9.52% |
-7.98% |
2024-08-27 |
AADI
Aadi Bioscience, Inc.
|
Buy |
10.29% |
-0.57% |
2024-08-27 |
PODD
Insulet Corporation
|
Buy |
10.5% |
1.11% |
2024-08-29 |
EGRX
Eagle Pharmaceuticals, Inc.
|
Buy |
9.3% |
-10.38% |
2024-08-29 |
TVTX
Travere Therapeutics, Inc.
|
Buy |
9.47% |
0% |
2024-09-04 |
ESPR
Esperion Therapeutics, Inc.
|
Buy |
9.47% |
0% |
2024-09-04 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
ARDX |
Sell
All
|
-11.62% |
NEOG |
Sell
All
|
-6.34% |
Assets Rebalanced
None
2024-08-29 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ARDX
Ardelyx, Inc.
|
Buy |
9.64% |
-3.45% |
2024-08-22 |
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
9.57% |
-4.2% |
2024-08-22 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
10.34% |
3.53% |
2024-08-22 |
CARA
Cara Therapeutics, Inc.
|
Buy |
10.37% |
3.79% |
2024-08-23 |
AGEN
Agenus Inc.
|
Buy |
9.33% |
-6.58% |
2024-08-23 |
CERS
Cerus Corporation
|
Buy |
9.39% |
-5.88% |
2024-08-27 |
AADI
Aadi Bioscience, Inc.
|
Buy |
9.58% |
-4% |
2024-08-27 |
NEOG
Neogen Corporation
|
Buy |
9.77% |
-2.15% |
2024-08-28 |
PODD
Insulet Corporation
|
Buy |
10.01% |
0% |
2024-08-29 |
EGRX
Eagle Pharmaceuticals, Inc.
|
Buy |
10.01% |
0% |
2024-08-29 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-08-28 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ARDX
Ardelyx, Inc.
|
Buy |
9.55% |
-2.35% |
2024-08-22 |
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
9.72% |
-0.64% |
2024-08-22 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
10.16% |
3.89% |
2024-08-22 |
CARA
Cara Therapeutics, Inc.
|
Buy |
10.24% |
4.66% |
2024-08-23 |
AGEN
Agenus Inc.
|
Buy |
10.07% |
2.93% |
2024-08-23 |
CERS
Cerus Corporation
|
Buy |
9.53% |
-2.52% |
2024-08-27 |
AADI
Aadi Bioscience, Inc.
|
Buy |
9.38% |
-4% |
2024-08-27 |
NEOG
Neogen Corporation
|
Buy |
9.78% |
0% |
2024-08-28 |
The percentage of cash held in the portfolio is:
21.57%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-08-27 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ARDX
Ardelyx, Inc.
|
Buy |
9.51% |
-0.94% |
2024-08-22 |
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
9.6% |
-0.05% |
2024-08-22 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
10.28% |
7.07% |
2024-08-22 |
CARA
Cara Therapeutics, Inc.
|
Buy |
10.36% |
7.87% |
2024-08-23 |
AGEN
Agenus Inc.
|
Buy |
10.3% |
7.31% |
2024-08-23 |
CERS
Cerus Corporation
|
Buy |
9.59% |
0% |
2024-08-27 |
AADI
Aadi Bioscience, Inc.
|
Buy |
9.59% |
0% |
2024-08-27 |
The percentage of cash held in the portfolio is:
30.77%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-08-23 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ARDX
Ardelyx, Inc.
|
Buy |
9.4% |
-5.02% |
2024-08-22 |
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
9.72% |
-1.79% |
2024-08-22 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.61% |
-2.83% |
2024-08-22 |
CARA
Cara Therapeutics, Inc.
|
Buy |
9.9% |
0% |
2024-08-23 |
AGEN
Agenus Inc.
|
Buy |
9.9% |
0% |
2024-08-23 |
The percentage of cash held in the portfolio is:
51.48%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-08-22 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ARDX
Ardelyx, Inc.
|
Buy |
9.8% |
0% |
2024-08-22 |
APLS
Apellis Pharmaceuticals, Inc.
|
Buy |
9.8% |
0% |
2024-08-22 |
ORGO
Organogenesis Holdings Inc.
|
Buy |
9.8% |
0% |
2024-08-22 |
The percentage of cash held in the portfolio is:
70.6%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-08-19 00:00:00
: Portfolio change date
No Asset in the portfolio
The percentage of cash held in the portfolio is:
100%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
CYH |
Sell
All
|
-1.57% |
Assets Rebalanced
None
2024-08-08 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
CYH
Community Health Systems, Inc.
|
Buy |
9.14% |
-7.66% |
2024-07-29 |
The percentage of cash held in the portfolio is:
90.86%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
RMD |
Sell
All
|
1.39% |
RCM |
Sell
All
|
7.14% |
Assets Rebalanced
None
2024-08-06 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
RCM
R1 RCM Inc.
|
Buy |
9.53% |
7.06% |
2024-07-18 |
CYH
Community Health Systems, Inc.
|
Buy |
9.33% |
-5.3% |
2024-07-29 |
RMD
ResMed Inc.
|
Buy |
9.11% |
3.67% |
2024-07-31 |
The percentage of cash held in the portfolio is:
72.03%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
BKD |
Sell
All
|
-5.42% |
FATE |
Sell
All
|
7.71% |
Assets Rebalanced
None
2024-08-05 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
BKD
Brookdale Senior Living Inc.
|
Buy |
12.18% |
-1.06% |
2024-07-16 |
FATE
Fate Therapeutics, Inc.
|
Buy |
14.65% |
19.02% |
2024-07-16 |
RCM
R1 RCM Inc.
|
Buy |
9.35% |
7.83% |
2024-07-18 |
CYH
Community Health Systems, Inc.
|
Buy |
9.4% |
-1.96% |
2024-07-29 |
RMD
ResMed Inc.
|
Buy |
9.2% |
7.5% |
2024-07-31 |
The percentage of cash held in the portfolio is:
45.23%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
HQY |
Sell
All
|
-11.82% |
HCSG |
Sell
All
|
-6.49% |
Assets Rebalanced
None
2024-08-01 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
BKD
Brookdale Senior Living Inc.
|
Buy |
12.19% |
2.25% |
2024-07-16 |
FATE
Fate Therapeutics, Inc.
|
Buy |
16.33% |
37.02% |
2024-07-16 |
RCM
R1 RCM Inc.
|
Buy |
8.3% |
-1.15% |
2024-07-18 |
CYH
Community Health Systems, Inc.
|
Buy |
9.6% |
3.34% |
2024-07-29 |
HQY
HealthEquity, Inc.
|
Buy |
9.01% |
-3.09% |
2024-07-29 |
HCSG
Healthcare Services Group, Inc.
|
Buy |
8.44% |
-1.12% |
2024-07-30 |
RMD
ResMed Inc.
|
Buy |
8.49% |
2.5% |
2024-07-31 |
The percentage of cash held in the portfolio is:
27.63%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
PDSB |
Sell
All
|
1.14% |
OPK |
Sell
All
|
7.58% |
Assets Rebalanced
None
2024-07-31 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
PDSB
PDS Biotechnology Corporation
|
Buy |
8.26% |
-1.7% |
2024-07-11 |
OPK
OPKO Health, Inc.
|
Buy |
9.1% |
8.33% |
2024-07-11 |
BKD
Brookdale Senior Living Inc.
|
Buy |
12.45% |
3.44% |
2024-07-16 |
FATE
Fate Therapeutics, Inc.
|
Buy |
15.88% |
31.88% |
2024-07-16 |
RCM
R1 RCM Inc.
|
Buy |
8.39% |
-1% |
2024-07-18 |
CYH
Community Health Systems, Inc.
|
Buy |
9.51% |
1.38% |
2024-07-29 |
HQY
HealthEquity, Inc.
|
Buy |
9.09% |
-3.16% |
2024-07-29 |
HCSG
Healthcare Services Group, Inc.
|
Buy |
8.58% |
-0.43% |
2024-07-30 |
RMD
ResMed Inc.
|
Buy |
8.37% |
0% |
2024-07-31 |
The percentage of cash held in the portfolio is:
10.37%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
SMTI |
Sell
All
|
-8.69% |
CLDX |
Sell
All
|
-12.36% |
Assets Rebalanced
None
2024-07-30 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
PDSB
PDS Biotechnology Corporation
|
Buy |
8.86% |
8.52% |
2024-07-11 |
OPK
OPKO Health, Inc.
|
Buy |
8.84% |
8.33% |
2024-07-11 |
BKD
Brookdale Senior Living Inc.
|
Buy |
12.2% |
4.37% |
2024-07-16 |
FATE
Fate Therapeutics, Inc.
|
Buy |
16.26% |
39.07% |
2024-07-16 |
RCM
R1 RCM Inc.
|
Buy |
8.02% |
-2.61% |
2024-07-18 |
CLDX
Celldex Therapeutics, Inc.
|
Buy |
8.6% |
-4.26% |
2024-07-26 |
SMTI
Sanara MedTech Inc.
|
Buy |
8.62% |
-5.45% |
2024-07-29 |
CYH
Community Health Systems, Inc.
|
Buy |
9.27% |
1.77% |
2024-07-29 |
HQY
HealthEquity, Inc.
|
Buy |
8.96% |
-1.69% |
2024-07-29 |
HCSG
Healthcare Services Group, Inc.
|
Buy |
8.37% |
0% |
2024-07-30 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
PTGX |
Sell
All
|
-7.35% |
Assets Rebalanced
None
2024-07-29 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
PDSB
PDS Biotechnology Corporation
|
Buy |
8.8% |
10.23% |
2024-07-11 |
OPK
OPKO Health, Inc.
|
Buy |
8.95% |
12.12% |
2024-07-11 |
BKD
Brookdale Senior Living Inc.
|
Buy |
12.09% |
5.69% |
2024-07-16 |
FATE
Fate Therapeutics, Inc.
|
Buy |
15.99% |
39.85% |
2024-07-16 |
RCM
R1 RCM Inc.
|
Buy |
8.04% |
-0.19% |
2024-07-18 |
PTGX
Protagonist Therapeutics, Inc.
|
Buy |
8.46% |
-3.84% |
2024-07-25 |
CLDX
Celldex Therapeutics, Inc.
|
Buy |
8.93% |
1.6% |
2024-07-26 |
SMTI
Sanara MedTech Inc.
|
Buy |
8.91% |
0% |
2024-07-29 |
CYH
Community Health Systems, Inc.
|
Buy |
8.91% |
0% |
2024-07-29 |
HQY
HealthEquity, Inc.
|
Buy |
8.91% |
0% |
2024-07-29 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
ATRC |
Sell
All
|
-12.65% |
Assets Rebalanced
None
2024-07-26 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
PDSB
PDS Biotechnology Corporation
|
Buy |
8.93% |
11.93% |
2024-07-11 |
OPK
OPKO Health, Inc.
|
Buy |
8.58% |
7.58% |
2024-07-11 |
BKD
Brookdale Senior Living Inc.
|
Buy |
11.82% |
3.44% |
2024-07-16 |
FATE
Fate Therapeutics, Inc.
|
Buy |
15.87% |
38.82% |
2024-07-16 |
ATRC
AtriCure, Inc.
|
Buy |
9.75% |
-7% |
2024-07-17 |
RCM
R1 RCM Inc.
|
Buy |
7.98% |
-0.84% |
2024-07-18 |
PTGX
Protagonist Therapeutics, Inc.
|
Buy |
8.72% |
-0.76% |
2024-07-25 |
CLDX
Celldex Therapeutics, Inc.
|
Buy |
8.78% |
0% |
2024-07-26 |
The percentage of cash held in the portfolio is:
19.57%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-07-25 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
PDSB
PDS Biotechnology Corporation
|
Buy |
8.58% |
6.96% |
2024-07-11 |
OPK
OPKO Health, Inc.
|
Buy |
8.63% |
7.58% |
2024-07-11 |
BKD
Brookdale Senior Living Inc.
|
Buy |
11.93% |
3.7% |
2024-07-16 |
FATE
Fate Therapeutics, Inc.
|
Buy |
15.31% |
33.16% |
2024-07-16 |
ATRC
AtriCure, Inc.
|
Buy |
10% |
-5.18% |
2024-07-17 |
RCM
R1 RCM Inc.
|
Buy |
8.17% |
0.92% |
2024-07-18 |
PTGX
Protagonist Therapeutics, Inc.
|
Buy |
8.84% |
0% |
2024-07-25 |
The percentage of cash held in the portfolio is:
28.53%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-07-23 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
PDSB
PDS Biotechnology Corporation
|
Buy |
9.01% |
10.8% |
2024-07-11 |
OPK
OPKO Health, Inc.
|
Buy |
9% |
10.61% |
2024-07-11 |
BKD
Brookdale Senior Living Inc.
|
Buy |
11.98% |
2.78% |
2024-07-16 |
FATE
Fate Therapeutics, Inc.
|
Buy |
13.67% |
17.22% |
2024-07-16 |
ATRC
AtriCure, Inc.
|
Buy |
10.07% |
-5.85% |
2024-07-17 |
RCM
R1 RCM Inc.
|
Buy |
8.39% |
2.15% |
2024-07-18 |
The percentage of cash held in the portfolio is:
37.89%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
VRDN |
Sell
All
|
13.4% |
Assets Rebalanced
None
2024-07-22 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
VRDN
Viridian Therapeutics, Inc.
|
Buy |
10.24% |
9.54% |
2024-07-02 |
PDSB
PDS Biotechnology Corporation
|
Buy |
9.05% |
9.94% |
2024-07-11 |
OPK
OPKO Health, Inc.
|
Buy |
9.29% |
12.88% |
2024-07-11 |
BKD
Brookdale Senior Living Inc.
|
Buy |
11.94% |
1.19% |
2024-07-16 |
FATE
Fate Therapeutics, Inc.
|
Buy |
12.95% |
9.77% |
2024-07-16 |
ATRC
AtriCure, Inc.
|
Buy |
10.33% |
-4.47% |
2024-07-17 |
RCM
R1 RCM Inc.
|
Buy |
8.47% |
2% |
2024-07-18 |
The percentage of cash held in the portfolio is:
27.73%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
ALT |
Sell
All
|
-16.04% |
Assets Rebalanced
None
2024-07-19 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
VRDN
Viridian Therapeutics, Inc.
|
Buy |
10.18% |
9.54% |
2024-07-02 |
PDSB
PDS Biotechnology Corporation
|
Buy |
8.98% |
9.66% |
2024-07-11 |
ALT
Altimmune, Inc.
|
Buy |
7.17% |
-12.43% |
2024-07-11 |
OPK
OPKO Health, Inc.
|
Buy |
9.43% |
15.15% |
2024-07-11 |
BKD
Brookdale Senior Living Inc.
|
Buy |
11.92% |
1.59% |
2024-07-16 |
FATE
Fate Therapeutics, Inc.
|
Buy |
13% |
10.8% |
2024-07-16 |
ATRC
AtriCure, Inc.
|
Buy |
10.49% |
-2.49% |
2024-07-17 |
RCM
R1 RCM Inc.
|
Buy |
8.14% |
-1.46% |
2024-07-18 |
The percentage of cash held in the portfolio is:
20.7%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
CYH |
Sell
All
|
17.81% |
WST |
Sell
All
|
-5.09% |
Assets Rebalanced
None
2024-07-18 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
CYH
Community Health Systems, Inc.
|
Buy |
11.12% |
23.12% |
2024-06-28 |
VRDN
Viridian Therapeutics, Inc.
|
Buy |
10.43% |
15.37% |
2024-07-02 |
PDSB
PDS Biotechnology Corporation
|
Buy |
9.07% |
13.92% |
2024-07-11 |
ALT
Altimmune, Inc.
|
Buy |
7.97% |
0.13% |
2024-07-11 |
OPK
OPKO Health, Inc.
|
Buy |
8.56% |
7.58% |
2024-07-11 |
WST
West Pharmaceutical Services, Inc.
|
Buy |
7.73% |
-1.88% |
2024-07-12 |
BKD
Brookdale Senior Living Inc.
|
Buy |
11.66% |
2.25% |
2024-07-16 |
FATE
Fate Therapeutics, Inc.
|
Buy |
13.07% |
14.65% |
2024-07-16 |
ATRC
AtriCure, Inc.
|
Buy |
10.36% |
-0.91% |
2024-07-17 |
RCM
R1 RCM Inc.
|
Buy |
8.03% |
0% |
2024-07-18 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
BHVN |
Sell
All
|
0.3% |
Assets Rebalanced
None
2024-07-17 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
CYH
Community Health Systems, Inc.
|
Buy |
11.03% |
25% |
2024-06-28 |
VRDN
Viridian Therapeutics, Inc.
|
Buy |
10.67% |
20.89% |
2024-07-02 |
PDSB
PDS Biotechnology Corporation
|
Buy |
9.15% |
17.76% |
2024-07-11 |
BHVN
Biohaven Ltd.
|
Buy |
8.15% |
4.86% |
2024-07-11 |
ALT
Altimmune, Inc.
|
Buy |
8.42% |
8.29% |
2024-07-11 |
OPK
OPKO Health, Inc.
|
Buy |
8.48% |
9.09% |
2024-07-11 |
WST
West Pharmaceutical Services, Inc.
|
Buy |
7.6% |
-1.26% |
2024-07-12 |
BKD
Brookdale Senior Living Inc.
|
Buy |
11.24% |
0.93% |
2024-07-16 |
FATE
Fate Therapeutics, Inc.
|
Buy |
13.03% |
16.97% |
2024-07-16 |
ATRC
AtriCure, Inc.
|
Buy |
10.21% |
0% |
2024-07-17 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
RARE |
Sell
All
|
13.6% |
Assets Rebalanced
None
2024-07-16 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
RARE
Ultragenyx Pharmaceutical Inc.
|
Buy |
10.47% |
11.57% |
2024-06-26 |
CYH
Community Health Systems, Inc.
|
Buy |
11.15% |
21.88% |
2024-06-28 |
VRDN
Viridian Therapeutics, Inc.
|
Buy |
10.17% |
11.2% |
2024-07-02 |
PDSB
PDS Biotechnology Corporation
|
Buy |
9.67% |
20.03% |
2024-07-11 |
BHVN
Biohaven Ltd.
|
Buy |
8.56% |
6.27% |
2024-07-11 |
ALT
Altimmune, Inc.
|
Buy |
8.51% |
5.61% |
2024-07-11 |
OPK
OPKO Health, Inc.
|
Buy |
8.73% |
8.33% |
2024-07-11 |
WST
West Pharmaceutical Services, Inc.
|
Buy |
7.66% |
-3.96% |
2024-07-12 |
BKD
Brookdale Senior Living Inc.
|
Buy |
11.54% |
0% |
2024-07-16 |
FATE
Fate Therapeutics, Inc.
|
Buy |
11.54% |
0% |
2024-07-16 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
ACAD |
Sell
All
|
13.54% |
EGRX |
Sell
All
|
33.26% |
Assets Rebalanced
None
2024-07-12 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ACAD
ACADIA Pharmaceuticals Inc.
|
Buy |
10.77% |
11.15% |
2024-06-25 |
EGRX
Eagle Pharmaceuticals, Inc.
|
Buy |
13.04% |
34.6% |
2024-06-25 |
RARE
Ultragenyx Pharmaceutical Inc.
|
Buy |
10.67% |
10.14% |
2024-06-26 |
CYH
Community Health Systems, Inc.
|
Buy |
10.95% |
15.94% |
2024-06-28 |
VRDN
Viridian Therapeutics, Inc.
|
Buy |
9.26% |
-1.97% |
2024-07-02 |
PDSB
PDS Biotechnology Corporation
|
Buy |
9.17% |
10.23% |
2024-07-11 |
BHVN
Biohaven Ltd.
|
Buy |
8.73% |
4.89% |
2024-07-11 |
ALT
Altimmune, Inc.
|
Buy |
8.54% |
2.67% |
2024-07-11 |
OPK
OPKO Health, Inc.
|
Buy |
8.63% |
3.79% |
2024-07-11 |
WST
West Pharmaceutical Services, Inc.
|
Buy |
8.24% |
0% |
2024-07-12 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-07-11 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ACAD
ACADIA Pharmaceuticals Inc.
|
Buy |
10.87% |
7.75% |
2024-06-25 |
EGRX
Eagle Pharmaceuticals, Inc.
|
Buy |
13.61% |
34.82% |
2024-06-25 |
RARE
Ultragenyx Pharmaceutical Inc.
|
Buy |
10.76% |
6.55% |
2024-06-26 |
CYH
Community Health Systems, Inc.
|
Buy |
10.27% |
4.37% |
2024-06-28 |
VRDN
Viridian Therapeutics, Inc.
|
Buy |
9.14% |
-7.12% |
2024-07-02 |
PDSB
PDS Biotechnology Corporation
|
Buy |
8.67% |
0% |
2024-07-11 |
BHVN
Biohaven Ltd.
|
Buy |
8.67% |
0% |
2024-07-11 |
ALT
Altimmune, Inc.
|
Buy |
8.67% |
0% |
2024-07-11 |
OPK
OPKO Health, Inc.
|
Buy |
8.67% |
0% |
2024-07-11 |
The percentage of cash held in the portfolio is:
10.67%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-07-10 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ACAD
ACADIA Pharmaceuticals Inc.
|
Buy |
10.89% |
7.87% |
2024-06-25 |
EGRX
Eagle Pharmaceuticals, Inc.
|
Buy |
13.67% |
35.49% |
2024-06-25 |
RARE
Ultragenyx Pharmaceutical Inc.
|
Buy |
10.7% |
6.02% |
2024-06-26 |
CYH
Community Health Systems, Inc.
|
Buy |
10.21% |
3.75% |
2024-06-28 |
VRDN
Viridian Therapeutics, Inc.
|
Buy |
9.2% |
-6.59% |
2024-07-02 |
The percentage of cash held in the portfolio is:
45.34%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
NVRO |
Sell
All
|
-11.61% |
Assets Rebalanced
None
2024-07-04 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ACAD
ACADIA Pharmaceuticals Inc.
|
Buy |
10.09% |
-1.83% |
2024-06-25 |
EGRX
Eagle Pharmaceuticals, Inc.
|
Buy |
12.62% |
22.77% |
2024-06-25 |
RARE
Ultragenyx Pharmaceutical Inc.
|
Buy |
10.37% |
0.9% |
2024-06-26 |
CYH
Community Health Systems, Inc.
|
Buy |
10.55% |
5.31% |
2024-06-28 |
NVRO
Nevro Corp.
|
Buy |
9.76% |
-2.67% |
2024-07-02 |
VRDN
Viridian Therapeutics, Inc.
|
Buy |
9.3% |
-7.27% |
2024-07-02 |
The percentage of cash held in the portfolio is:
37.31%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
STAA |
Sell
All
|
1.87% |
Assets Rebalanced
None
2024-07-03 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ACAD
ACADIA Pharmaceuticals Inc.
|
Buy |
10.23% |
-0.25% |
2024-06-25 |
EGRX
Eagle Pharmaceuticals, Inc.
|
Buy |
11.98% |
16.74% |
2024-06-25 |
STAA
STAAR Surgical Company
|
Buy |
10.8% |
5.2% |
2024-06-26 |
RARE
Ultragenyx Pharmaceutical Inc.
|
Buy |
10.55% |
2.79% |
2024-06-26 |
CYH
Community Health Systems, Inc.
|
Buy |
10.72% |
7.19% |
2024-06-28 |
NVRO
Nevro Corp.
|
Buy |
9.71% |
-3.02% |
2024-07-02 |
VRDN
Viridian Therapeutics, Inc.
|
Buy |
9.21% |
-7.95% |
2024-07-02 |
The percentage of cash held in the portfolio is:
26.8%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
CHRS |
Sell
All
|
-19.65% |
MNKD |
Sell
All
|
-7.37% |
ARDX |
Sell
All
|
-28.74% |
Assets Rebalanced
None
2024-07-02 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ACAD
ACADIA Pharmaceuticals Inc.
|
Buy |
9.71% |
1.01% |
2024-06-25 |
MNKD
MannKind Corporation
|
Buy |
9.01% |
-6.26% |
2024-06-25 |
EGRX
Eagle Pharmaceuticals, Inc.
|
Buy |
11.86% |
23.44% |
2024-06-25 |
STAA
STAAR Surgical Company
|
Buy |
10.77% |
12.05% |
2024-06-26 |
RARE
Ultragenyx Pharmaceutical Inc.
|
Buy |
9.92% |
3.19% |
2024-06-26 |
CYH
Community Health Systems, Inc.
|
Buy |
9.72% |
3.75% |
2024-06-28 |
ARDX
Ardelyx, Inc.
|
Buy |
9.56% |
2.16% |
2024-07-01 |
CHRS
Coherus BioSciences, Inc.
|
Buy |
8.71% |
-6.94% |
2024-07-01 |
NVRO
Nevro Corp.
|
Buy |
9.37% |
0% |
2024-07-02 |
VRDN
Viridian Therapeutics, Inc.
|
Buy |
9.37% |
0% |
2024-07-02 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-07-01 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ACAD
ACADIA Pharmaceuticals Inc.
|
Buy |
9.72% |
2.33% |
2024-06-25 |
MNKD
MannKind Corporation
|
Buy |
9.14% |
-3.87% |
2024-06-25 |
EGRX
Eagle Pharmaceuticals, Inc.
|
Buy |
11.88% |
25% |
2024-06-25 |
STAA
STAAR Surgical Company
|
Buy |
10.69% |
12.5% |
2024-06-26 |
RARE
Ultragenyx Pharmaceutical Inc.
|
Buy |
9.8% |
3.14% |
2024-06-26 |
CYH
Community Health Systems, Inc.
|
Buy |
9.73% |
5% |
2024-06-28 |
ARDX
Ardelyx, Inc.
|
Buy |
9.26% |
0% |
2024-07-01 |
CHRS
Coherus BioSciences, Inc.
|
Buy |
9.26% |
0% |
2024-07-01 |
The percentage of cash held in the portfolio is:
20.52%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-06-28 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ACAD
ACADIA Pharmaceuticals Inc.
|
Buy |
9.96% |
3.09% |
2024-06-25 |
MNKD
MannKind Corporation
|
Buy |
9.41% |
-2.58% |
2024-06-25 |
EGRX
Eagle Pharmaceuticals, Inc.
|
Buy |
10.82% |
12.05% |
2024-06-25 |
STAA
STAAR Surgical Company
|
Buy |
10.68% |
10.52% |
2024-06-26 |
RARE
Ultragenyx Pharmaceutical Inc.
|
Buy |
10.04% |
3.94% |
2024-06-26 |
CYH
Community Health Systems, Inc.
|
Buy |
9.42% |
0% |
2024-06-28 |
The percentage of cash held in the portfolio is:
39.67%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-06-27 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ACAD
ACADIA Pharmaceuticals Inc.
|
Buy |
9.56% |
-2.39% |
2024-06-25 |
MNKD
MannKind Corporation
|
Buy |
9.37% |
-4.42% |
2024-06-25 |
EGRX
Eagle Pharmaceuticals, Inc.
|
Buy |
10.76% |
9.82% |
2024-06-25 |
STAA
STAAR Surgical Company
|
Buy |
10.54% |
7.54% |
2024-06-26 |
RARE
Ultragenyx Pharmaceutical Inc.
|
Buy |
9.97% |
1.71% |
2024-06-26 |
The percentage of cash held in the portfolio is:
49.8%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
FGEN |
Sell
All
|
-12.08% |
Assets Rebalanced
None
2024-06-26 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ACAD
ACADIA Pharmaceuticals Inc.
|
Buy |
9.69% |
-1.76% |
2024-06-25 |
MNKD
MannKind Corporation
|
Buy |
9.51% |
-3.5% |
2024-06-25 |
FGEN
FibroGen, Inc.
|
Buy |
9.61% |
-2.5% |
2024-06-25 |
EGRX
Eagle Pharmaceuticals, Inc.
|
Buy |
10.01% |
1.56% |
2024-06-25 |
STAA
STAAR Surgical Company
|
Buy |
9.86% |
0% |
2024-06-26 |
RARE
Ultragenyx Pharmaceutical Inc.
|
Buy |
9.86% |
0% |
2024-06-26 |
The percentage of cash held in the portfolio is:
41.45%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-06-25 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ACAD
ACADIA Pharmaceuticals Inc.
|
Buy |
9.8% |
0% |
2024-06-25 |
MNKD
MannKind Corporation
|
Buy |
9.8% |
0% |
2024-06-25 |
FGEN
FibroGen, Inc.
|
Buy |
9.8% |
0% |
2024-06-25 |
EGRX
Eagle Pharmaceuticals, Inc.
|
Buy |
9.8% |
0% |
2024-06-25 |
The percentage of cash held in the portfolio is:
60.8%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-05-27 00:00:00
: Portfolio change date
No Asset in the portfolio
The percentage of cash held in the portfolio is:
100%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
OMCL |
Sell
All
|
8.3% |
Assets Rebalanced
None
2024-05-24 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
OMCL
Omnicell, Inc.
|
Buy |
11.36% |
5.21% |
2024-05-06 |
The percentage of cash held in the portfolio is:
88.64%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
VCYT |
Sell
All
|
-7.38% |
Assets Rebalanced
None
2024-05-23 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
OMCL
Omnicell, Inc.
|
Buy |
11.5% |
7% |
2024-05-06 |
VCYT
Veracyte, Inc.
|
Buy |
8.95% |
-3.91% |
2024-05-14 |
The percentage of cash held in the portfolio is:
79.55%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
PODD |
Sell
All
|
-2.32% |
INGN |
Sell
All
|
22.55% |
ACRS |
Sell
All
|
-8.73% |
SGMO |
Sell
All
|
18.52% |
Assets Rebalanced
None
2024-05-22 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
INGN
Inogen, Inc.
|
Buy |
11.65% |
22.13% |
2024-05-02 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
8.93% |
-6.35% |
2024-05-02 |
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
10.6% |
11.11% |
2024-05-02 |
OMCL
Omnicell, Inc.
|
Buy |
11.44% |
5.91% |
2024-05-06 |
VCYT
Veracyte, Inc.
|
Buy |
9.06% |
-3.2% |
2024-05-14 |
PODD
Insulet Corporation
|
Buy |
8.38% |
-1.4% |
2024-05-17 |
The percentage of cash held in the portfolio is:
39.94%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
SENS |
Sell
All
|
-3.49% |
Assets Rebalanced
None
2024-05-21 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
SENS
Senseonics Holdings, Inc.
|
Buy |
9.17% |
-3.7% |
2024-05-01 |
INGN
Inogen, Inc.
|
Buy |
11.82% |
24.26% |
2024-05-02 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
8.98% |
-5.56% |
2024-05-02 |
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
10.74% |
12.96% |
2024-05-02 |
OMCL
Omnicell, Inc.
|
Buy |
10.98% |
1.99% |
2024-05-06 |
VCYT
Veracyte, Inc.
|
Buy |
9.25% |
-0.89% |
2024-05-14 |
PODD
Insulet Corporation
|
Buy |
8.42% |
-0.67% |
2024-05-17 |
The percentage of cash held in the portfolio is:
30.63%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
CARA |
Sell
All
|
-0.79% |
Assets Rebalanced
None
2024-05-20 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
CARA
Cara Therapeutics, Inc.
|
Buy |
9.32% |
-0.79% |
2024-04-30 |
SENS
Senseonics Holdings, Inc.
|
Buy |
9.36% |
-0.41% |
2024-05-01 |
INGN
Inogen, Inc.
|
Buy |
11.75% |
25.25% |
2024-05-02 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
8.86% |
-5.56% |
2024-05-02 |
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
11.29% |
20.37% |
2024-05-02 |
OMCL
Omnicell, Inc.
|
Buy |
10.73% |
1.03% |
2024-05-06 |
VCYT
Veracyte, Inc.
|
Buy |
9.36% |
1.69% |
2024-05-14 |
PODD
Insulet Corporation
|
Buy |
8.44% |
1.02% |
2024-05-17 |
The percentage of cash held in the portfolio is:
20.9%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
IBRX |
Sell
All
|
-14.91% |
PTCT |
Sell
All
|
15.84% |
Assets Rebalanced
None
2024-05-17 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
PTCT
PTC Therapeutics, Inc.
|
Buy |
11.06% |
19.11% |
2024-04-29 |
IBRX
ImmunityBio, Inc.
|
Buy |
8% |
-13.79% |
2024-04-30 |
CARA
Cara Therapeutics, Inc.
|
Buy |
9.88% |
6.48% |
2024-04-30 |
SENS
Senseonics Holdings, Inc.
|
Buy |
9.38% |
1.03% |
2024-05-01 |
INGN
Inogen, Inc.
|
Buy |
11.77% |
26.95% |
2024-05-02 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
8.68% |
-6.35% |
2024-05-02 |
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
10.47% |
12.96% |
2024-05-02 |
OMCL
Omnicell, Inc.
|
Buy |
11.03% |
5.08% |
2024-05-06 |
VCYT
Veracyte, Inc.
|
Buy |
9.46% |
4% |
2024-05-14 |
PODD
Insulet Corporation
|
Buy |
8.26% |
0% |
2024-05-17 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
MD |
Sell
All
|
-8.68% |
Assets Rebalanced
None
2024-05-14 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
PTCT
PTC Therapeutics, Inc.
|
Buy |
10.57% |
10.96% |
2024-04-29 |
IBRX
ImmunityBio, Inc.
|
Buy |
9.14% |
-4% |
2024-04-30 |
CARA
Cara Therapeutics, Inc.
|
Buy |
9.45% |
-0.79% |
2024-04-30 |
SENS
Senseonics Holdings, Inc.
|
Buy |
8.68% |
-8.83% |
2024-05-01 |
INGN
Inogen, Inc.
|
Buy |
11.89% |
25.04% |
2024-05-02 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
8.91% |
-6.35% |
2024-05-02 |
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
9.69% |
1.85% |
2024-05-02 |
OMCL
Omnicell, Inc.
|
Buy |
11.01% |
2.22% |
2024-05-06 |
MD
Pediatrix Medical Group, Inc.
|
Buy |
9.34% |
0% |
2024-05-14 |
VCYT
Veracyte, Inc.
|
Buy |
9.34% |
0% |
2024-05-14 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-05-13 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
PTCT
PTC Therapeutics, Inc.
|
Buy |
10.86% |
12.88% |
2024-04-29 |
IBRX
ImmunityBio, Inc.
|
Buy |
8.68% |
-9.68% |
2024-04-30 |
CARA
Cara Therapeutics, Inc.
|
Buy |
9.11% |
-5.29% |
2024-04-30 |
SENS
Senseonics Holdings, Inc.
|
Buy |
9.2% |
-4.31% |
2024-05-01 |
INGN
Inogen, Inc.
|
Buy |
11.53% |
20% |
2024-05-02 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
8.92% |
-7.14% |
2024-05-02 |
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
9.96% |
3.7% |
2024-05-02 |
OMCL
Omnicell, Inc.
|
Buy |
10.87% |
-0.03% |
2024-05-06 |
The percentage of cash held in the portfolio is:
20.88%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
IOVA |
Sell
All
|
-12.24% |
Assets Rebalanced
None
2024-05-10 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
PTCT
PTC Therapeutics, Inc.
|
Buy |
10.21% |
8.68% |
2024-04-29 |
IBRX
ImmunityBio, Inc.
|
Buy |
8.42% |
-10.34% |
2024-04-30 |
CARA
Cara Therapeutics, Inc.
|
Buy |
9.44% |
0.53% |
2024-04-30 |
SENS
Senseonics Holdings, Inc.
|
Buy |
9.28% |
-1.23% |
2024-05-01 |
INGN
Inogen, Inc.
|
Buy |
11.57% |
23.26% |
2024-05-02 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
9.12% |
-2.78% |
2024-05-02 |
IOVA
Iovance Biotherapeutics, Inc.
|
Buy |
10.1% |
7.6% |
2024-05-02 |
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
9.04% |
-3.7% |
2024-05-02 |
OMCL
Omnicell, Inc.
|
Buy |
10.66% |
0.4% |
2024-05-06 |
The percentage of cash held in the portfolio is:
12.16%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
CDMO |
Sell
All
|
7.67% |
Assets Rebalanced
None
2024-05-06 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
PTCT
PTC Therapeutics, Inc.
|
Buy |
10.61% |
15.54% |
2024-04-29 |
IBRX
ImmunityBio, Inc.
|
Buy |
9.35% |
1.78% |
2024-04-30 |
CDMO
Avid Bioservices, Inc.
|
Buy |
10.02% |
9.13% |
2024-04-30 |
CARA
Cara Therapeutics, Inc.
|
Buy |
9.45% |
2.94% |
2024-04-30 |
SENS
Senseonics Holdings, Inc.
|
Buy |
9.53% |
3.68% |
2024-05-01 |
INGN
Inogen, Inc.
|
Buy |
9.3% |
1.42% |
2024-05-02 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
9.9% |
7.94% |
2024-05-02 |
IOVA
Iovance Biotherapeutics, Inc.
|
Buy |
10% |
9.04% |
2024-05-02 |
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
9.44% |
2.93% |
2024-05-02 |
OMCL
Omnicell, Inc.
|
Buy |
10.38% |
0% |
2024-05-06 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
SMMT |
Sell
All
|
13.73% |
Assets Rebalanced
None
2024-05-02 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
PTCT
PTC Therapeutics, Inc.
|
Buy |
11.35% |
19.57% |
2024-04-29 |
SMMT
Summit Therapeutics Inc.
|
Buy |
11.56% |
21.76% |
2024-04-29 |
IBRX
ImmunityBio, Inc.
|
Buy |
9.01% |
-5.01% |
2024-04-30 |
CDMO
Avid Bioservices, Inc.
|
Buy |
9.63% |
1.46% |
2024-04-30 |
CARA
Cara Therapeutics, Inc.
|
Buy |
9.53% |
0.4% |
2024-04-30 |
SENS
Senseonics Holdings, Inc.
|
Buy |
9.02% |
-4.93% |
2024-05-01 |
INGN
Inogen, Inc.
|
Buy |
9.48% |
0% |
2024-05-02 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
9.48% |
0% |
2024-05-02 |
IOVA
Iovance Biotherapeutics, Inc.
|
Buy |
9.48% |
0% |
2024-05-02 |
SGMO
Sangamo Therapeutics, Inc.
|
Buy |
9.48% |
0% |
2024-05-02 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-05-01 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
PTCT
PTC Therapeutics, Inc.
|
Buy |
10.99% |
12.53% |
2024-04-29 |
SMMT
Summit Therapeutics Inc.
|
Buy |
9.94% |
1.81% |
2024-04-29 |
IBRX
ImmunityBio, Inc.
|
Buy |
8.68% |
-11.12% |
2024-04-30 |
CDMO
Avid Bioservices, Inc.
|
Buy |
9.85% |
0.93% |
2024-04-30 |
CARA
Cara Therapeutics, Inc.
|
Buy |
9.71% |
-0.53% |
2024-04-30 |
SENS
Senseonics Holdings, Inc.
|
Buy |
9.77% |
0% |
2024-05-01 |
The percentage of cash held in the portfolio is:
41.06%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-04-30 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
PTCT
PTC Therapeutics, Inc.
|
Buy |
10.89% |
12.5% |
2024-04-29 |
SMMT
Summit Therapeutics Inc.
|
Buy |
9.73% |
0.52% |
2024-04-29 |
IBRX
ImmunityBio, Inc.
|
Buy |
9.67% |
0% |
2024-04-30 |
CDMO
Avid Bioservices, Inc.
|
Buy |
9.67% |
0% |
2024-04-30 |
CARA
Cara Therapeutics, Inc.
|
Buy |
9.67% |
0% |
2024-04-30 |
The percentage of cash held in the portfolio is:
50.37%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-04-29 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
PTCT
PTC Therapeutics, Inc.
|
Buy |
9.8% |
0% |
2024-04-29 |
SMMT
Summit Therapeutics Inc.
|
Buy |
9.8% |
0% |
2024-04-29 |
The percentage of cash held in the portfolio is:
80.4%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-04-23 00:00:00
: Portfolio change date
No Asset in the portfolio
The percentage of cash held in the portfolio is:
100%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
OPK |
Sell
All
|
-6.11% |
Assets Rebalanced
None
2024-04-18 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
OPK
OPKO Health, Inc.
|
Buy |
9.41% |
-4.58% |
2024-04-02 |
The percentage of cash held in the portfolio is:
90.59%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
ANGO |
Sell
All
|
11.05% |
KIDS |
Sell
All
|
3.21% |
ACRS |
Sell
All
|
-2.38% |
Assets Rebalanced
None
2024-04-16 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ANGO
AngioDynamics, Inc.
|
Buy |
11.48% |
10.7% |
2024-03-28 |
KIDS
OrthoPediatrics Corp.
|
Buy |
10.9% |
5.11% |
2024-03-28 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
9.96% |
-3.97% |
2024-03-28 |
OPK
OPKO Health, Inc.
|
Buy |
9.27% |
-6.11% |
2024-04-02 |
The percentage of cash held in the portfolio is:
58.39%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
TNDM |
Sell
All
|
-9.75% |
Assets Rebalanced
None
2024-04-15 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ANGO
AngioDynamics, Inc.
|
Buy |
11.5% |
11.75% |
2024-03-28 |
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
9.76% |
-5.1% |
2024-03-28 |
KIDS
OrthoPediatrics Corp.
|
Buy |
11.04% |
7.32% |
2024-03-28 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
9.88% |
-3.97% |
2024-03-28 |
OPK
OPKO Health, Inc.
|
Buy |
9.2% |
-6.11% |
2024-04-02 |
The percentage of cash held in the portfolio is:
48.63%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
RVNC |
Sell
All
|
-16.06% |
Assets Rebalanced
None
2024-04-11 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ANGO
AngioDynamics, Inc.
|
Buy |
12.13% |
20.18% |
2024-03-28 |
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
9.89% |
-2.07% |
2024-03-28 |
KIDS
OrthoPediatrics Corp.
|
Buy |
11.07% |
9.67% |
2024-03-28 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
9.29% |
-7.94% |
2024-03-28 |
RVNC
Revance Therapeutics, Inc.
|
Buy |
9.05% |
-10.37% |
2024-03-29 |
OPK
OPKO Health, Inc.
|
Buy |
9.32% |
-3.05% |
2024-04-02 |
The percentage of cash held in the portfolio is:
39.25%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
LXRX |
Sell
All
|
-15.83% |
Assets Rebalanced
None
2024-04-03 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ANGO
AngioDynamics, Inc.
|
Buy |
11.09% |
8.6% |
2024-03-28 |
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
9.69% |
-5.1% |
2024-03-28 |
KIDS
OrthoPediatrics Corp.
|
Buy |
9.41% |
-7.9% |
2024-03-28 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
9.89% |
-3.17% |
2024-03-28 |
RVNC
Revance Therapeutics, Inc.
|
Buy |
9.36% |
-8.33% |
2024-03-29 |
LXRX
Lexicon Pharmaceuticals, Inc.
|
Buy |
9.4% |
-7.92% |
2024-03-29 |
OPK
OPKO Health, Inc.
|
Buy |
10.02% |
3.05% |
2024-04-02 |
The percentage of cash held in the portfolio is:
31.12%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
VCYT |
Sell
All
|
-5.57% |
Assets Rebalanced
None
2024-04-02 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ANGO
AngioDynamics, Inc.
|
Buy |
10.31% |
2.28% |
2024-03-28 |
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
9.67% |
-4.11% |
2024-03-28 |
KIDS
OrthoPediatrics Corp.
|
Buy |
9.81% |
-2.69% |
2024-03-28 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
10.08% |
0% |
2024-03-28 |
VCYT
Veracyte, Inc.
|
Buy |
10.05% |
-0.37% |
2024-03-28 |
RVNC
Revance Therapeutics, Inc.
|
Buy |
9.69% |
-3.86% |
2024-03-29 |
LXRX
Lexicon Pharmaceuticals, Inc.
|
Buy |
9.58% |
-5% |
2024-03-29 |
OPK
OPKO Health, Inc.
|
Buy |
9.6% |
0% |
2024-04-02 |
The percentage of cash held in the portfolio is:
21.2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
OFIX |
Sell
All
|
-3.17% |
ATRI |
Sell
All
|
-11.81% |
Assets Rebalanced
None
2024-03-29 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ANGO
AngioDynamics, Inc.
|
Buy |
10.05% |
2.98% |
2024-03-28 |
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
9.79% |
0.31% |
2024-03-28 |
KIDS
OrthoPediatrics Corp.
|
Buy |
9.82% |
0.66% |
2024-03-28 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
9.6% |
-1.59% |
2024-03-28 |
VCYT
Veracyte, Inc.
|
Buy |
9.96% |
2.03% |
2024-03-28 |
ATRI
Atrion Corporation
|
Buy |
9.76% |
0% |
2024-03-29 |
OFIX
Orthofix Medical Inc.
|
Buy |
9.76% |
0% |
2024-03-29 |
RVNC
Revance Therapeutics, Inc.
|
Buy |
9.76% |
0% |
2024-03-29 |
LXRX
Lexicon Pharmaceuticals, Inc.
|
Buy |
9.76% |
0% |
2024-03-29 |
The percentage of cash held in the portfolio is:
11.76%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-03-28 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ANGO
AngioDynamics, Inc.
|
Buy |
9.8% |
0% |
2024-03-28 |
TNDM
Tandem Diabetes Care, Inc.
|
Buy |
9.8% |
0% |
2024-03-28 |
KIDS
OrthoPediatrics Corp.
|
Buy |
9.8% |
0% |
2024-03-28 |
ACRS
Aclaris Therapeutics, Inc.
|
Buy |
9.8% |
0% |
2024-03-28 |
VCYT
Veracyte, Inc.
|
Buy |
9.8% |
0% |
2024-03-28 |
The percentage of cash held in the portfolio is:
51%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
BAX |
Sell
All
|
-0.7% |
OMCL |
Sell
All
|
5.22% |
Assets Rebalanced
None
2024-03-25 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
BAX
Baxter International Inc.
|
Buy |
10.14% |
-2.44% |
2024-03-07 |
OMCL
Omnicell, Inc.
|
Buy |
10.44% |
0.5% |
2024-03-07 |
The percentage of cash held in the portfolio is:
79.42%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
THC |
Sell
All
|
8.23% |
RDNT |
Sell
All
|
8.32% |
NTRA |
Sell
All
|
3.25% |
Assets Rebalanced
None
2024-03-21 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
THC
Tenet Healthcare Corporation
|
Buy |
10.47% |
8.8% |
2024-03-04 |
RDNT
RadNet, Inc.
|
Buy |
10.25% |
6.45% |
2024-03-04 |
NTRA
Natera, Inc.
|
Buy |
10% |
3.9% |
2024-03-04 |
BAX
Baxter International Inc.
|
Buy |
10.12% |
-2.7% |
2024-03-07 |
OMCL
Omnicell, Inc.
|
Buy |
10.45% |
0.5% |
2024-03-07 |
The percentage of cash held in the portfolio is:
48.71%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
QTRX |
Sell
All
|
-9.55% |
Assets Rebalanced
None
2024-03-19 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
THC
Tenet Healthcare Corporation
|
Buy |
10.34% |
6.46% |
2024-03-04 |
RDNT
RadNet, Inc.
|
Buy |
9.82% |
1.08% |
2024-03-04 |
NTRA
Natera, Inc.
|
Buy |
9.79% |
0.79% |
2024-03-04 |
QTRX
Quanterix Corporation
|
Buy |
7.84% |
-5.31% |
2024-03-05 |
BAX
Baxter International Inc.
|
Buy |
10.14% |
-3.37% |
2024-03-07 |
OMCL
Omnicell, Inc.
|
Buy |
10.38% |
-1.15% |
2024-03-07 |
The percentage of cash held in the portfolio is:
41.69%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
ABUS |
Sell
All
|
-5.93% |
Assets Rebalanced
None
2024-03-18 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
THC
Tenet Healthcare Corporation
|
Buy |
10.16% |
4.78% |
2024-03-04 |
RDNT
RadNet, Inc.
|
Buy |
9.72% |
0.23% |
2024-03-04 |
NTRA
Natera, Inc.
|
Buy |
9.71% |
0.12% |
2024-03-04 |
QTRX
Quanterix Corporation
|
Buy |
7.81% |
-5.42% |
2024-03-05 |
BAX
Baxter International Inc.
|
Buy |
10.14% |
-3.21% |
2024-03-07 |
OMCL
Omnicell, Inc.
|
Buy |
10.44% |
-0.36% |
2024-03-07 |
ABUS
Arbutus Biopharma Corporation
|
Buy |
12.29% |
-2.96% |
2024-03-08 |
The percentage of cash held in the portfolio is:
29.71%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
PTGX |
Sell
All
|
1.76% |
Assets Rebalanced
None
2024-03-15 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
PTGX
Protagonist Therapeutics, Inc.
|
Buy |
10.06% |
-0.46% |
2024-02-26 |
THC
Tenet Healthcare Corporation
|
Buy |
10.34% |
6.1% |
2024-03-04 |
RDNT
RadNet, Inc.
|
Buy |
9.64% |
-1.08% |
2024-03-04 |
NTRA
Natera, Inc.
|
Buy |
9.56% |
-1.9% |
2024-03-04 |
QTRX
Quanterix Corporation
|
Buy |
7.8% |
-6.02% |
2024-03-05 |
BAX
Baxter International Inc.
|
Buy |
10.29% |
-2.26% |
2024-03-07 |
OMCL
Omnicell, Inc.
|
Buy |
10.45% |
-0.72% |
2024-03-07 |
ABUS
Arbutus Biopharma Corporation
|
Buy |
12.3% |
-3.33% |
2024-03-08 |
The percentage of cash held in the portfolio is:
19.56%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
MRSN |
Sell
All
|
-15.74% |
Assets Rebalanced
None
2024-03-13 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
PTGX
Protagonist Therapeutics, Inc.
|
Buy |
10.27% |
4.88% |
2024-02-26 |
THC
Tenet Healthcare Corporation
|
Buy |
10% |
6.01% |
2024-03-04 |
MRSN
Mersana Therapeutics, Inc.
|
Buy |
8.96% |
-5.05% |
2024-03-04 |
RDNT
RadNet, Inc.
|
Buy |
9.79% |
3.77% |
2024-03-04 |
NTRA
Natera, Inc.
|
Buy |
9.58% |
1.57% |
2024-03-04 |
QTRX
Quanterix Corporation
|
Buy |
7.68% |
-4.49% |
2024-03-05 |
BAX
Baxter International Inc.
|
Buy |
10.17% |
-0.23% |
2024-03-07 |
OMCL
Omnicell, Inc.
|
Buy |
10.3% |
1.04% |
2024-03-07 |
ABUS
Arbutus Biopharma Corporation
|
Buy |
12.27% |
-0.37% |
2024-03-08 |
The percentage of cash held in the portfolio is:
10.98%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
ENTA |
Sell
All
|
-5.28% |
Assets Rebalanced
None
2024-03-08 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
PTGX
Protagonist Therapeutics, Inc.
|
Buy |
10.37% |
8.46% |
2024-02-26 |
THC
Tenet Healthcare Corporation
|
Buy |
9.59% |
4.1% |
2024-03-04 |
MRSN
Mersana Therapeutics, Inc.
|
Buy |
9.08% |
-1.52% |
2024-03-04 |
ENTA
Enanta Pharmaceuticals, Inc.
|
Buy |
9.44% |
2.41% |
2024-03-04 |
RDNT
RadNet, Inc.
|
Buy |
10.09% |
9.45% |
2024-03-04 |
NTRA
Natera, Inc.
|
Buy |
9.45% |
2.52% |
2024-03-04 |
QTRX
Quanterix Corporation
|
Buy |
7.84% |
-0.07% |
2024-03-05 |
BAX
Baxter International Inc.
|
Buy |
10.07% |
1.16% |
2024-03-07 |
OMCL
Omnicell, Inc.
|
Buy |
10.05% |
0.97% |
2024-03-07 |
ABUS
Arbutus Biopharma Corporation
|
Buy |
12.03% |
0% |
2024-03-08 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
RCM |
Sell
All
|
27.04% |
Assets Rebalanced
None
2024-03-07 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
RCM
R1 RCM Inc.
|
Buy |
11.9% |
24.71% |
2024-02-16 |
PTGX
Protagonist Therapeutics, Inc.
|
Buy |
10.57% |
9.8% |
2024-02-26 |
THC
Tenet Healthcare Corporation
|
Buy |
9.58% |
3.23% |
2024-03-04 |
MRSN
Mersana Therapeutics, Inc.
|
Buy |
8.97% |
-3.37% |
2024-03-04 |
ENTA
Enanta Pharmaceuticals, Inc.
|
Buy |
9.47% |
2.02% |
2024-03-04 |
RDNT
RadNet, Inc.
|
Buy |
10.15% |
9.36% |
2024-03-04 |
NTRA
Natera, Inc.
|
Buy |
9.36% |
0.91% |
2024-03-04 |
QTRX
Quanterix Corporation
|
Buy |
7.96% |
0.75% |
2024-03-05 |
BAX
Baxter International Inc.
|
Buy |
10.02% |
0% |
2024-03-07 |
OMCL
Omnicell, Inc.
|
Buy |
10.02% |
0% |
2024-03-07 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
NUTX |
Sell
All
|
-12.3% |
BRKR |
Sell
All
|
13.09% |
Assets Rebalanced
None
2024-03-05 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
NUTX
Nutex Health Inc.
|
Buy |
9.34% |
-6.56% |
2024-02-15 |
BRKR
Bruker Corporation
|
Buy |
11.24% |
12.49% |
2024-02-15 |
RCM
R1 RCM Inc.
|
Buy |
11.96% |
25.25% |
2024-02-16 |
PTGX
Protagonist Therapeutics, Inc.
|
Buy |
10.7% |
11.13% |
2024-02-26 |
THC
Tenet Healthcare Corporation
|
Buy |
9.23% |
-0.63% |
2024-03-04 |
MRSN
Mersana Therapeutics, Inc.
|
Buy |
8.99% |
-3.2% |
2024-03-04 |
ENTA
Enanta Pharmaceuticals, Inc.
|
Buy |
9.47% |
1.95% |
2024-03-04 |
RDNT
RadNet, Inc.
|
Buy |
9.81% |
5.61% |
2024-03-04 |
NTRA
Natera, Inc.
|
Buy |
9.37% |
0.89% |
2024-03-04 |
QTRX
Quanterix Corporation
|
Buy |
7.91% |
0% |
2024-03-05 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
RVNC |
Sell
All
|
-14.99% |
Assets Rebalanced
None
2024-03-04 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
NUTX
Nutex Health Inc.
|
Buy |
9.2% |
-7.38% |
2024-02-15 |
BRKR
Bruker Corporation
|
Buy |
10.95% |
10.34% |
2024-02-15 |
RCM
R1 RCM Inc.
|
Buy |
11.9% |
25.34% |
2024-02-16 |
PTGX
Protagonist Therapeutics, Inc.
|
Buy |
10.81% |
12.89% |
2024-02-26 |
RVNC
Revance Therapeutics, Inc.
|
Buy |
9.02% |
-2.24% |
2024-03-01 |
THC
Tenet Healthcare Corporation
|
Buy |
9.23% |
0% |
2024-03-04 |
MRSN
Mersana Therapeutics, Inc.
|
Buy |
9.23% |
0% |
2024-03-04 |
ENTA
Enanta Pharmaceuticals, Inc.
|
Buy |
9.23% |
0% |
2024-03-04 |
RDNT
RadNet, Inc.
|
Buy |
9.23% |
0% |
2024-03-04 |
NTRA
Natera, Inc.
|
Buy |
9.23% |
0% |
2024-03-04 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
None
Assets Rebalanced
None
2024-03-01 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
NUTX
Nutex Health Inc.
|
Buy |
9.25% |
-7.38% |
2024-02-15 |
BRKR
Bruker Corporation
|
Buy |
10.79% |
8.11% |
2024-02-15 |
RCM
R1 RCM Inc.
|
Buy |
12.01% |
25.78% |
2024-02-16 |
PTGX
Protagonist Therapeutics, Inc.
|
Buy |
10.27% |
6.67% |
2024-02-26 |
RVNC
Revance Therapeutics, Inc.
|
Buy |
9.28% |
0% |
2024-03-01 |
The percentage of cash held in the portfolio is:
48.4%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
CARA |
Sell
All
|
32.4% |
NVAX |
Sell
All
|
14.88% |
VRDN |
Sell
All
|
-7.24% |
Assets Rebalanced
None
2024-02-29 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
NUTX
Nutex Health Inc.
|
Buy |
9.15% |
-8.2% |
2024-02-15 |
BRKR
Bruker Corporation
|
Buy |
10.77% |
8.03% |
2024-02-15 |
RCM
R1 RCM Inc.
|
Buy |
12.28% |
28.83% |
2024-02-16 |
NVAX
Novavax, Inc.
|
Buy |
9.77% |
2.56% |
2024-02-16 |
CARA
Cara Therapeutics, Inc.
|
Buy |
11.03% |
38.63% |
2024-02-21 |
PTGX
Protagonist Therapeutics, Inc.
|
Buy |
10.27% |
6.85% |
2024-02-26 |
VRDN
Viridian Therapeutics, Inc.
|
Buy |
8.68% |
0% |
2024-02-29 |
The percentage of cash held in the portfolio is:
28.05%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
CUTR |
Sell
All
|
-32.07% |
RGNX |
Sell
All
|
36.58% |
INGN |
Sell
All
|
-38.03% |
Assets Rebalanced
None
2024-02-28 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
RGNX
REGENXBIO Inc.
|
Buy |
11.69% |
37.41% |
2024-02-08 |
NUTX
Nutex Health Inc.
|
Buy |
8.39% |
-8.2% |
2024-02-15 |
BRKR
Bruker Corporation
|
Buy |
9.56% |
4.56% |
2024-02-15 |
CUTR
Cutera, Inc.
|
Buy |
8.32% |
-8.97% |
2024-02-15 |
RCM
R1 RCM Inc.
|
Buy |
11.41% |
30.53% |
2024-02-16 |
INGN
Inogen, Inc.
|
Buy |
8.04% |
-7.98% |
2024-02-16 |
NVAX
Novavax, Inc.
|
Buy |
12.23% |
40% |
2024-02-16 |
CARA
Cara Therapeutics, Inc.
|
Buy |
10.76% |
47.35% |
2024-02-21 |
PTGX
Protagonist Therapeutics, Inc.
|
Buy |
9.16% |
3.9% |
2024-02-26 |
The percentage of cash held in the portfolio is:
10.44%
New Assets Added
None
Assets Removed
Asset |
Action |
Perf % |
ATRI |
Sell
All
|
0.86% |
Assets Rebalanced
None
2024-02-26 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
ATRI
Atrion Corporation
|
Buy |
9.19% |
0.57% |
2024-02-07 |
RGNX
REGENXBIO Inc.
|
Buy |
10.91% |
19.49% |
2024-02-08 |
NUTX
Nutex Health Inc.
|
Buy |
9.49% |
-3.28% |
2024-02-15 |
BRKR
Bruker Corporation
|
Buy |
10.38% |
5.77% |
2024-02-15 |
CUTR
Cutera, Inc.
|
Buy |
8.12% |
-17.24% |
2024-02-15 |
RCM
R1 RCM Inc.
|
Buy |
9.32% |
-0.63% |
2024-02-16 |
INGN
Inogen, Inc.
|
Buy |
8.5% |
-9.46% |
2024-02-16 |
NVAX
Novavax, Inc.
|
Buy |
11.54% |
23.02% |
2024-02-16 |
CARA
Cara Therapeutics, Inc.
|
Buy |
11.07% |
41.28% |
2024-02-21 |
PTGX
Protagonist Therapeutics, Inc.
|
Buy |
9.46% |
0% |
2024-02-26 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
NTLA |
Sell
All
|
3.2% |
Assets Rebalanced
None
2024-02-21 00:00:00
: Portfolio change date
Asset |
Action |
Weight |
PnL |
Entry Date |
NTLA
Intellia Therapeutics, Inc.
|
Buy |
10.27% |
7.35% |
2024-02-05 |
ATRI
Atrion Corporation
|
Buy |
9.66% |
2.22% |
2024-02-07 |
RGNX
REGENXBIO Inc.
|
Buy |
12.03% |
27.25% |
2024-02-08 |
NUTX
Nutex Health Inc.
|
Buy |
9.58% |
-5.74% |
2024-02-15 |
BRKR
Bruker Corporation
|
Buy |
10.3% |
1.31% |
2024-02-15 |
CUTR
Cutera, Inc.
|
Buy |
10.27% |
1.03% |
2024-02-15 |
RCM
R1 RCM Inc.
|
Buy |
9.37% |
-3.58% |
2024-02-16 |
INGN
Inogen, Inc.
|
Buy |
9.08% |
-6.5% |
2024-02-16 |
NVAX
Novavax, Inc.
|
Buy |
9.33% |
-3.95% |
2024-02-16 |
CARA
Cara Therapeutics, Inc.
|
Buy |
8.11% |
0% |
2024-02-21 |
The percentage of cash held in the portfolio is:
2%
New Assets Added
Assets Removed
Asset |
Action |
Perf % |
MRSN |
Sell
All
|
-14.18% |
Assets Rebalanced
None